A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K48/00 C12N15/87

C12N15/11

According to International Patent-Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) A61K C12N IPC 7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, CHEM ABS Data

DOCUME	ENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
ategory °	Citation of document, with indication, where appropriate, of the	nelevani to ciami vo.	
(GOMEZ ET AL.: "Cytoplasmic p2" protects U937 promonocytic cel mediated apoptosis" 'Online! 24 May 2002 (2002-05-24), XP00 Retrieved from the Internet: URL:WWW.RETROCONFERENCE.ORG/20 3446.PDF> 'retrieved on 2005-0 cited in the application the whole document	1-6	
Υ	WO 01/88191 A (THE UNITED STAT AMERICA AS REPRESENTED BY THE OF VETER) 22 November 2001 (20 the whole document	DELAKTREMI	1-7, 13-18, 24-29
X Fi	urther documents are listed in the continuation of box C.	X Patent family members are lister	d in annex.
"A" docu con "E" earli filin "L" docu whi cite "O" doci oth "P" doci late	ment defining the general state of the art which is not sidered to be of particular relevance or document but published on or after the international g date ment which may throw doubts on priority claim(s) or ch is cited to establish the publication date of another tition or other special reason (as specified) ment referring to an oral disclosure, use, exhibition or er means ment published prior to the international filing date but than the priority date claimed the actual completion of the international search	"T" later document published after the ir or priority date and not in conflict will cited to understand the principle or invention. "X" document of particular relevance; the cannot be considered novel or can involve an inventive step when the "Y" document of particular relevance; the cannot be considered to involve an document is combined with one or ments, such combination being obtain the art. "&" document member of the same pate. Date of mailing of the international step in the art.	theory underlying the e claimed invention not be considered to document is taken alone e claimed invention inventive step when the more other such docu- vious to a person skilled ent family
L	19 April 2005	Authorized officer	
Name a	nd mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Fotaki, M	

Ir ational Application No
PCT/US2004/036492

	PC1/US2004/036492	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
KAWATA SANAE ET AL: "p21Waf1/Cip1/Sdi1 prevents apoptosis as well as stimulates growth in cells transformed or immortalized by human T-cell leukemia virus type 1-encoded Tax." JOURNAL OF VIROLOGY, vol. 77, no. 13, July 2003 (2003-07), pages 7291-7299, XP002324904 ISSN: 0022-538X the whole document	1-7, 13-18, 24-29	
POLUHA WOJCIECH ET AL: "The cyclin-dependent kinase inhibitor p21-WAF1 is required for survival of differentiating neuroblastoma cells" MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 4, 1996, pages 1335-1341, XP002325238 ISSN: 0270-7306 the whole document	1-7, 13-18, 24-29	
TIAN HUI ET AL: "p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis" CANCER RESEARCH, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 679-684, XP002325239 ISSN: 0008-5472 the whole document	1-7, 13-18, 24-29	
GARTEL ANDREI L ET AL: "The role of the cyclin-dependent kinase inhibitor p21 in apoptosis" MOLECULAR CANCER THERAPEUTICS, vol. 1, no. 8, June 2002 (2002-06), pages 639-649, XP002325181 ISSN: 1535-7163		
	prevents apoptosis as well as stimulates growth in cells transformed or immortalized by human T-cell leukemia virus type 1-encoded Tax." JOURNAL OF VIROLOGY, vol. 77, no. 13, July 2003 (2003-07), pages 7291-7299, XPO02324904 ISSN: 0022-538X the whole document POLUHA WOJCIECH ET AL: "The cyclin-dependent kinase inhibitor p21-WAF1 is required for survival of differentiating neuroblastoma cells" MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 4, 1996, pages 1335-1341, XP002325238 ISSN: 0270-7306 the whole document TIAN HUI ET AL: "p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis" CANCER RESEARCH, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 679-684, XP002325239 ISSN: 0008-5472 the whole document GARTEL ANDREI L ET AL: "The role of the cyclin-dependent kinase inhibitor p21 in apoptosis" MOLECULAR CANCER THERAPEUTICS, vol. 1, no. 8, June 2002 (2002-06), pages 639-649, XP002325181	

International application No. PCT/US2004/036492

Box II Observations where certain claims were found unsearchable (Continuation of item 2	of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for	the following reasons:
1. X Claims Nos.: 13–18 because they relate to subject matter not required to be searched by this Authority, namely: Although claims 13–18 are directed to a method of	of treatment of
the human/animal body, the search has been carried out and baalleged effects of the compound/composition.	ased on the
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requan extent that no meaningful International Search can be carried out, specifically:	uirements to such
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third senter.	nces of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first shee	t)
This International Searching Authority found multiple inventions in this international application, as follows:	
see additional sheet	
As all required additional search fees were timely paid by the applicant, this International Search Repo searchable claims.	ort covers all
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did of any additional fee.	not invite payment
3. As only some of the required additional search fees were timely paid by the applicant, this Internationa covers only those claims for which fees were paid, specifically claims Nos.:	l Search Report
4. X No required additional search fees were timely paid by the applicant. Consequently, this International S restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-7, 13-18, 24-29 (all partially)	Search Report is
Remark on Protest The additional-search fees were accompanied by t No protest accompanied the payment of additional	
	•

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-7, 13-18, 24-29 (all partially)

Method for attenuating transmission or infection by an immunodeficiency virus by providing an inhibitor of p21 to a cell wherein said inhibitor is a polynucleotide comprising at least 10 contiguous nucleotides of SEQ ID NO:8; a method of treating AIDS by providing the same inhibitor; a pharmaceutical composition comprising the same inhibitor

2. claims: 1-7, 13-18, 24-29 (all partially)

The same as invention 1 but for SEQ ID NO:10

3. claims: 1-4, 8-10, 13-15, 19-21, 24-26, 30-32 (all parially)

The same as invention 1 but for SEQ ID NO:7

4. claims: 1-4, 8-10, 13-15, 19-21, 24-26, 30-32 (all parially)

The same as invention 1 but for SEQ ID NO:9

5. claims: 11, 12, 22, 23, 33, 34 (all entirely); 1-4, 13-15, 24-26 (all partially)

The same as invention 1 wherein said inhibitor is 2-cyano-3, 12-dioxooleana-1,9-dien-28-oic acid (CDDO)

Information on patent family members

	Ir ational Application No
1	PCT/US2004/036492

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 0188191 /	22-11-2001	AU WO US US	5305101 A 0188191 A1 2003144236 A1 2005043262 A1	26-11-2001 22-11-2001 31-07-2003 24-02-2005